NOCIL Q1 FY27 Earnings Call — Analysis (NSE: NOCIL)
NOCIL Q1 FY27 revenue up 20% YoY to ₹403 Cr; guides FY27E revenue ₹1,400-1,600 Cr with ~10% EBITDA margin, TDQ ramp starts Q4FY27
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
Q1FY27 Revenue ₹403 Cr ( +20% YoY ) . New guidance — FY27 fy27 full-year revenue ₹1,400 to ₹1,600 Cr . New story: Anti-dumping duty protection .
Results
Revenue ₹403 Cr (+20% YoY, +22% QoQ); EBITDA ₹45 Cr (+48% YoY, 11.2% margin); PAT ₹28 Cr (+61% YoY); 9% YoY volume growth offset by 3% QoQ decline from supply-side constraints.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹403 Cr | +20% | yoy · Q1FY27 |
| Revenue | ₹403 Cr | +22% | qoq · Q1FY27 |
| Volume Growth | 9% | +9% | yoy · Q1FY27 |
| Volume Growth | (3%) | −3% | qoq · Q1FY27 |
| EBITDA | ₹45 Cr | +48% | yoy · Q1FY27 |
| EBITDA | ₹45 Cr | +115% | qoq · Q1FY27 |
| EBITDA Margin | 11.2% | +210 bps | yoy · Q1FY27 |
| EBITDA Margin | 11.2% | +480 bps | qoq · Q1FY27 |
| PBT | ₹37 Cr | +60% | yoy · Q1FY27 |
| PAT | ₹28 Cr | +61% | yoy · Q1FY27 |
Guidance
FY27 revenue guided ₹1,400-1,600 Cr, EBITDA ~10%, volume growth ~10%; TDQ first commercial volumes expected Q4FY27, anti-dumping duty on Pilflex 13 expected to be approved.
What management committed to
- FY27 revenue is expected to be in the range of ₹1,400-1,600 crores based on the current pricing environment. — ₹1,400 to ₹1,600 crores, FY27
- FY27 EBITDA margin is expected to be around 10%. — 10%, FY27
- Volume growth for FY27 is expected to be around 10% over FY26. — 10%, FY27
- TDQ plant [in Dahej] first commercial supplies will start trickling in Q4 FY27, with more meaningful volumes in Q1 FY28. — Q4FY27
- NOCIL expects the Government of India to approve the anti-dumping duty on Pilflex 13 based on the positive DGTR recommendation; management is quite positive on the outcome. — Q2FY27
- Export volume mix is expected to reach 40-45% by FY28-29. — 40% to 45%, FY29
- Specialty segment will add at least another 5% to 10% to overall revenue mix from current ~15% level, aided by the new expansion over the next 1-2 years. — 5% to 10%, FY29
- Deferred volumes from Q1 FY27 supply-side constraints will be recovered in the coming quarters. — coming quarters
- One-off elevated costs in Q1 FY27 (freight, utility, maintenance, CSR front-loading) will normalize, and a few crores of maintenance cost will not repeat. — a few crores, subsequent quarters
Key themes
Anti-dumping gains, TDQ ramp, and supply-chain headwinds
How the narrative shifted
- Anti-dumping duty protection: Anti-dumping on CBS/NS approved, Pilflex 13 recommendation positive; management expects duty to strengthen domestic pricing and margins.
- Input cost and logistics volatility: Middle East war drives up freight, gas prices, and utility costs, creating short-term headwinds that are deemed one-off but remain uncertain.
- TDQ plant as growth catalyst: New TDQ antioxidant plant in Dahej in trial production; customer samples under approval; first commercial supplies expected Q4FY27, driving both domestic and export volumes.
- Export market expansion amid Chinese competition: Exports at 33% of volumes, directionally expected to reach 40-45% by FY28-29; Chinese competitors benefit from subsidies, but NOCIL maintains competitiveness with anti-dumping cover.
- Temporary supply disruptions masking demand: 3% QoQ volume decline attributed to operational/logistics constraints, not demand; underlying demand seen as healthy; deferred volumes to be recovered.
- Product mix shift to specialty chemicals: Specialty segment currently ~15% of revenue, expected to gain 5-10 percentage points in 1-2 years from new product development and expansions.
- Domestic tyre demand resilience: Healthy domestic tyre replacement and OEM demand, aided by GST 2.0 and infrastructure, provides volume tailwind; near-term seasonal moderation expected but temporary.
Operational commentary
- Domestic volumes registered double-digit growth supported by improved demand from GST 2.0 implementation.
- Export volumes recorded single-digit growth from ongoing customer engagements and international traction; export mix at 33% of volumes.
- Sequential volume decline of 3% QoQ due to temporary supply-side constraints – utility and logistical challenges from Middle East war, plus maintenance – postponing certain orders; management confident of recovering deferred volumes in coming quarters.
- Non-tyre segment saw temporary demand contraction from sharp input cost increases and labour shortage (cooking gas shortages); expected to normalise.
- Anti-dumping duty on Sulphonamides (CBS, NS) approved by Central Government on 20 June 2026.
- DGTR issued positive final recommendation for anti-dumping duty on Pilflex 13 in June 2026; government approval awaited.
- Trial production at new TDQ plant in Dahej underway; customer samples initiated; approvals expected over 6-8 months with first commercial volumes likely Q4FY27.
- New ₹130 Cr investment in Dahej progressing on track despite recent war-related disruptions.
- R&D teams working closely with customers on new products; positive traction expected during FY27.
Analyst Q&A
Q. Can the Q1 EBITDA run rate be sustainable given low-cost RMC benefit this quarter?
Overall for the year with volume growth and operating leverage, we expect to hover around 10% EBITDA.
Q. Quantify one-off costs that won't repeat next quarter.
A few crores will come down on account of one-off maintenance cost, etc. Utility costs depend on oil prices. Employee cost will stabilize.
Q. Promoter share pledging – why is promoter holding getting pledged again?
We cannot comment on that. That’s promoters in their offices call. So, we prefer to remain non-committal.
Q. What has changed in terms of capacity or profitability of Pilflex 13 between the last ADD application and now?
The product can be catered entirely by domestic manufacturing and all domestic producers are under stress on account of dumping; it is even more severe compared to the previous period.
Q. Has INR depreciation against USD/CNY benefited volumes or import substitution?
We have not seen a significant impact. Chinese players are continuing to adjust their yuan prices downwards, and rubber chemicals still enjoy export subsidies.
Q. How much of topline will be covered under the ADD excluding TDQ?
This would be totally about 25% to 30%.
Q. What could be the EBITDA benefit from the ADD?
It's a bit premature today. We don't know how much foreign players will absorb.
Research and educational content only. Not investment advice.